Immunotherapy combo shows promise against tough esophageal cancer

NCT ID NCT02998268

First seen Apr 20, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with locally advanced esophageal adenocarcinoma. About 42 adults whose cancer has not spread far but is too large for immediate surgery will receive the combination treatment. The main goal is to see if more tumors shrink or disappear completely after treatment, which may improve long-term survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • USC Keck School of Medicine, Norris Cancer Center

    Los Angeles, California, 90033, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109-5848, United States

  • Weill Cornell Medicine

    New York, New York, 10068, United States

Conditions

Explore the condition pages connected to this study.